Dizal (688192.SS) announced the results from the phase 3 WU-KONG28 study showing that ZEGFROVY monotherapy demonstrated superior anti-tumor efficacy, compared to platinum-doublet chemotherapy, in untreated NSCLC patients with EGFR exon 20 insertion mutations.
Xiaolin Zhang, CEO of Dizal, said: "WU-KONG28 study demonstrates that ZEGFROVY can provide superior benefits for treatment naïve patients. It is the first positive study for this difficult disease, providing a chemotherapy-free option for patients globally. It is the first global phase 3 study conducted by Dizal."
ZEGFROVY has previously been granted accelerated approvals in the U.S. and China for the treatment of relapsed or refractory EGFR exon 20 ins NSCLC. The NDA for ZEGFROVY as a first-line treatment for EGFR exon 20 ins NSCLC has been accepted and granted Priority Review designation by China's National Medical Products Administration.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.